| Drug General Information |
| Drug ID |
D07JMN
|
| Former ID |
DNC009124
|
| Drug Name |
1-(pyridin-2-yl)piperazine
|
| Synonyms |
1-Pyridin-2-yl-piperazine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C9H13N3
|
| Canonical SMILES |
C1CN(CCN1)C2=CC=CC=N2
|
| InChI |
1S/C9H13N3/c1-2-4-11-9(3-1)12-7-5-10-6-8-12/h1-4,10H,5-8H2
|
| InChIKey |
GZRKXKUVVPSREJ-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Phospholipase D1 |
Target Info |
Inhibitor |
[2]
|
|---|
| Alpha-2A adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
| Alpha-1D adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
| Alpha-1A adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
| Alpha-2B adrenergic receptor |
Target Info |
Inhibitor |
[1]
|
|
BioCyc Pathway
|
Phospholipases
|
|
KEGG Pathway
|
Glycerophospholipid metabolism
|
|
Ether lipid metabolism
|
|
Metabolic pathways
|
|
Ras signaling pathway
|
|
cAMP signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Endocytosis
|
|
Fc gamma R-mediated phagocytosis
|
|
Glutamatergic synapse
|
|
GnRH signaling pathway
|
|
Pathways in cancer
|
|
Pancreatic cancer
|
|
Choline metabolism in cancerhsa04022:cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Adrenergic signaling in cardiomyocytes
|
|
Vascular smooth muscle contraction
|
|
Salivary secretionhsa04020:Calcium signaling pathway
|
|
AMPK signaling pathway
|
|
Salivary secretionhsa04022:cGMP-PKG signaling pathway
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
Ras PathwayP00002:Alpha adrenergic receptor signaling pathwayP00002:Alpha adrenergic receptor signaling pathwayP00002:Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Pathway Interaction Database
|
RhoA signaling pathway
|
|
Arf6 trafficking events
|
|
CDC42 signaling events
|
|
Arf6 downstream pathway
|
|
mTOR signaling pathway
|
|
ErbB1 downstream signaling
|
|
IL8- and CXCR1-mediated signaling events
|
|
Alpha-synuclein signaling
|
|
Reactome
|
Role of phospholipids in phagocytosisR-HSA-390696:Adrenoceptors
|
|
Adrenaline signalling through Alpha-2 adrenergic receptor
|
|
Adrenaline,noradrenaline inhibits insulin secretion
|
|
G alpha (i) signalling events
|
|
G alpha (z) signalling events
|
|
Surfactant metabolismR-HSA-390696:Adrenoceptors
|
|
G alpha (q) signalling events
|
|
G alpha (12/13) signalling eventsR-HSA-390696:Adrenoceptors
|
|
WikiPathways
|
EGF/EGFR Signaling Pathway
|
|
TSH signaling pathwayWP58:Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Platelet Aggregation (Plug Formation)
|
|
Integration of energy metabolism
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP58:Monoamine GPCRs
|
|
Calcium Regulation in the Cardiac Cell
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCR downstream signaling
|
|
GPCRs, OtherWP58:Monoamine GPCRs
|
|
Endothelin Pathways
|
|
AMPK SignalingWP58:Monoamine GPCRs
|
| References |
| REF 1 | J Med Chem. 1984 Sep;27(9):1182-5.Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. |
|---|
| REF 2 | Bioorg Med Chem Lett. 2009 Apr 15;19(8):2240-3. Epub 2009 Mar 6.Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity. |
|---|
